Preclinical Cancer Models

Preclinical Evaluation Team

  • Closely monitors the course of disease with efficacy studies of drug candidates in vitro and in vivo
  • Combinatorial and relapse therapy evaluation
  • Develop molecular and in vivo imaging endpoints
  • Biodistribution (PK/PD)
  • Biomarkers/molecular signatures of treatment response, and mechanisms of resistance analysis

Research and Development Team

  • Derivation, modification and validation of better predictive GEM models, also for “unmet need” and clinically challenging cancer types
  • Biomarkers/molecular signatures predictive of early stages and progression to advanced disease
  • Breeding strategies for scale-up of mouse cohorts

Technology and Optimization Team

  • New methodologies for expanding and scaling up preclinical study design
  • ES and iPSC technologies for non-germline cohorts and preservation
  • Optimization/retooling of best available GEMs for preclinical drug development workflows

If you are interested in partnering with CAPR to assist in your preclinical assessment, contact:

Histopathology and Biobanking Support

Model development and preclinical assessment studies conducted by CAPR scientists are extensively supported by state-of-the-art histopathology, including automated tissue processing and immunostaining, followed by application of image acquisition and quantitative analysis techniques. Samples of tissue biopsies, biological fluids and macromolecules (proteins, nucleic acids, metabolites) are systematically annotated for biobanking.

Integrated Approach to Optimized Drug Development (iGXT© Platform)

To implement a transdisciplinary platform in a clinically relevant manner for enhanced development of novel efficacious drugs and precision therapies, integrating the strength of a cross-model comparison approach, CAPR launched a collaborative effort with nationally recognized clinical centers and organizations developing preclinical approaches in primary patient-derived xenograft (pdx) models – a strategy referred to as iGXT (integrated GEM models, patient-derived Xenograft, clinical Trials), applicable both to a broad spectrum of cancer types and to other diseases.

Program and Project Management

Supported by experienced dedicated project managers, CAPR strives to complete studies on time and within allocated budgets employing best practices of contemporary project management during initiation, planning, execution, monitoring, and closing phases of every project.